Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit.
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
received:
13
10
2021
accepted:
04
02
2022
pubmed:
24
3
2022
medline:
18
5
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
To assess the incidence of remission of type 2 diabetes in routine care settings. People with type 2 diabetes (HbA1c ≥48 mmol/mol [6.5%] or <48 mmol/mol [6.5%] with a prescription for glucose-lowering medications) alive on 1 April 2018 were identified from a national collation of health records in England and followed until 31 December 2019. Remission was defined as two HbA1c measurements of <48 mmol/mol (6.5%) at least 182 days apart, with no prescription for glucose-lowering medications 90 days before these measurements. In 2,297,700 people with type 2 diabetes, the overall incidence of remission per 1,000 person-years was 9.7 (95% CI 9.6-9.8) and 44.9 (95% CI 44.0-45.7) in 75,610 (3.3%) people who were diagnosed <1 year. In addition to shorter duration of diagnosis, baseline factors associated with higher odds of remission were no prescription for glucose-lowering medication, lower HbA1c and BMI, BMI reduction, White ethnicity, female sex, and lower socioeconomic deprivation. Among 8,940 (0.4%) with characteristics associated with remission (diagnosed <2 years, HbA1c <53 mmol/mol [7.0%], prescribed metformin alone or no glucose-lowering medications, BMI reduction of ≥10%), incidence of remission per 1,000 person-years was 83.2 (95% CI 78.7-87.9). Remission of type 2 diabetes was generally infrequent in routine care settings but may be a reasonable goal for a subset of people who lose a significant amount of weight shortly after diagnosis. Policies that encourage intentional remission of type 2 diabetes should seek to reduce the ethnic and socioeconomic inequalities identified.
Identifiants
pubmed: 35320360
pii: 144853
doi: 10.2337/dc21-2136
pmc: PMC9174970
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Banques de données
figshare
['10.2337/figshare.19165148']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1151-1161Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom
Informations de copyright
© 2022 by the American Diabetes Association.
Références
JAMA. 2014 Jun 11;311(22):2297-304
pubmed: 24915261
Diabetes Care. 2016 Jun;39(6):924-33
pubmed: 27222550
Diabetologia. 2020 Aug;63(8):1542-1553
pubmed: 32435821
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Lancet. 2018 Feb 10;391(10120):541-551
pubmed: 29221645
Diabet Med. 2021 Sep;38(9):e14616
pubmed: 34062007
Diabetes Care. 2014 Dec;37(12):3188-95
pubmed: 25231895
Diabetes Care. 2012 Aug;35(8):1746-8
pubmed: 22699291
Diabet Med. 2020 Apr;37(4):681-688
pubmed: 31479535
Diabetes Metab Res Rev. 2018 Sep;34(6):e3015
pubmed: 29663623
Diabetes Care. 2021 Aug 30;:
pubmed: 34462270
N Engl J Med. 2012 Apr 26;366(17):1577-85
pubmed: 22449317
JAMA. 2012 Dec 19;308(23):2489-96
pubmed: 23288372
Lancet Diabetes Endocrinol. 2019 May;7(5):344-355
pubmed: 30852132
Diabetologia. 2016 May;59(5):945-53
pubmed: 26983924
Diabet Med. 2012 Feb;29(2):181-9
pubmed: 21883428